Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 vs placebo in ankylosing spondylitis (China, phase 3)
CTR20160889Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Started Dec 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20160889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160889.